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The impact of the direction of HLA mismatch (MM) on outcome in unrelated cord blood (UCB) transplantation
has not yet been clariﬁed. We conducted a retrospective study using national registry data on 2977 patients
who underwent transplantation using a single UCB for leukemia or myelodysplastic syndrome. HLA matching
was assessed by serologic data for HLA-A, -B, and -DR loci. The median age of the recipients at transplantation
was 41 years (range, 0-82 years), and 2300 recipients (77%) were age 16 years. The 2-year overall survival
rate was 0.46. The presence of MM only in the graft-versus-host direction or only in the host-versus-graft
direction was not associated with overall mortality (hazard ratio [HR], 0.88; P ¼ .317 and HR, 0.95;
P ¼ .670, respectively) compared with 1 bidirectional MM. This ﬁnding was consistent in both the child and
adult cohorts. The presence of MM only in the graft-versus-host direction was associated with a lower
incidence of nonrelapse mortality (HR, 0.65; P ¼ .040), signiﬁcant only in the child cohort. No MM category
was associated with relapse. Our ﬁndings suggest that the direction of HLA MM does not have a signiﬁcant
impact on overall survival after UCB transplantation.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Unrelated cord blood (UCB) has emerged as a promising
alternative source of hematopoietic stem cells for adult and
pediatric allogeneic hematopoietic cell transplantation [1-4],
and the use of UCB transplantation (UCBT) has been rapidly
increasing, particularly in the United States, Europe, and
Japan. One advantage of using UCB as a hematopoietic stem
cell source is that UCBT requires less stringent HLA matching
compared with bone marrow or peripheral blood stem cell
transplantation, making it easier to ﬁnd candidate UCB units
in UCB banks. One or 2 antigen/allele mismatches (MMs) inedgments on page 254.
quests: Yoshinobu Kanda, MD, Division
Center, Jichi Medical University, 1-847
City, Saitama 330-8503, Japan.
in.ac.jp (Y. Kanda).
2013 American Society for Blood and Marrow
12.09.017the HLA-A, -B, and -DR loci between a UCB unit and recipient
are acceptable without ex vivo T cell depletion methods, and
the clinical outcome of transplantation using a 0-2 antigen/
allele-mismatched UCB unit was almost comparable to that
from an HLA allele-matched unrelated donor [1-3].
Although the number of HLA MMs between a UCB unit
and a recipient is usually counted without considering the
MM direction, the effect of the immune reaction caused by
HLAMM differs according to whether the MM is in the graft-
versus-host (GVH) or host-versus-graft (HVG) direction. A
mismatched antigen in the GVH direction can be a major
target for donor T cells and can cause graft-versus-host
disease (GVHD), whereas a mismatched antigen in the HVG
direction can be a major target for the remaining recipient T
cells and can lead to graft rejection. In related trans-
plantation, the presence of HLA MMs in the GVH direction is
associated with a higher incidence of GVHD, whereas theTransplantation.
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a higher incidence of rejection [5-7]. Therefore, from a bio-
logical perspective, the impact of HLA MM should be dis-
cussed separately according to the direction of MM.
However, because most patients have an equal number of
MMs in the GVH and HVG directions (bidirectional MM),
studying an adequate number of patients to evaluate an MM
imbalance in the GVH and HVG directions has proven
difﬁcult.
The few studies that have evaluated the impact of the HLA
MM direction on UCBT outcome have reported inconsistent
results [8-10]. Matsuno et al. [8] reported that an HLA MM in
the GVH direction was associated with lower incidence of
neutrophil engraftment. In contrast, Stevens et al. [9] showed
that UCBT with an MM only in the GVH direction was asso-
ciated with a lower incidence of nonrelapse mortality (NRM)
and overall mortality compared with UCBT with an 1 bidi-
rectional MM, whereas UCBT with an MM only in the HVG
direction was associated with a lower incidence of neutro-
phil engraftment and a higher incidence of relapse.
To clarify the signiﬁcance of the direction of HLA MM on
transplantation outcomes, we conducted a retrospective
study using national registry data in 2977 patients who
underwent a single UCBT.
METHODS
Data Collection
Data for 2987 patients with acute myelogenous leukemia (AML), acute
lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and
chronic myelogenous leukemia (CML) who underwent a ﬁrst trans-
plantation using a single UCB unit between January 1, 1998, and December
31, 2009, were obtained from the Transplant Registry Uniﬁed Management
Program (TRUMP) [11], in which all UCBTs are registered through the Japan
Cord Blood Bank Network (JCBBN), a national network of all 11 cord blood
banks in Japan. Ten patients lacking data on survival status or survival date
were excluded. A total of 2977 patients met the criteria for study inclusion.
The study design was approved by the TRUMP Data Management
Committee and the Institutional Review Board of Saitama Medical Center,
Jichi Medical University, where this study was organized.
Histocompatibility
Histocompatibility data for the HLA-A, -B, and -DR loci were obtained
from reports collected from the institution at which the transplantationwas
performed or cord blood banks. HLA typing methods have been described
previously [12]. To reﬂect current practice in Japan, HLA matching was
assessed by serologic data for HLA-A, -B, and -DR loci. A secondary analysis
using antigen level data for HLA-A, -B and available allele level data for HLA-
DRB1 was also performed to compare our data with previously published
data from the United States and Europe. HLA-DRB1 allele information was
available in 84% of patients (2498 of 2977). Among these patients, 62% had
the same number of MMs at HLA-DRB1 loci at either the antigen or allele
level. An HLA MM in the GVH direction was deﬁned as when the recipient’s
antigens or alleles were not shared by the donor, and an MM in the HVG
direction was deﬁned as when the donor’s antigens or alleles were not
shared by the recipient.
Endpoints
The primary study endpoint was overall survival (OS). Other endpoints
assessed were relapse, NRM, neutrophil and platelet engraftment, grade II-
IV or III-IV acute GVHD, and chronic GVHD. Neutrophil recovery was deﬁned
as an absolute neutrophil count exceeding 0.5109/L for 3 consecutive days
after UCBT. Platelet recovery was deﬁned as an absolute platelet count
exceeding 50  109/L without platelet transfusion. The physicians who
performed transplantation at each center diagnosed and graded acute and
chronic GVHD according to traditional criteria [13,14]. The incidence of acute
GVHD was evaluated in patients who engrafted, and that of chronic GVHD
was evaluated in patients who engrafted and survived for more than 100
days.
Statistical Analysis
The probability of OS was estimated according to the KaplaneMeier
method and the groups were compared using the log-rank test. The prob-
abilities of relapse, NRM, neutrophil and platelet engraftment, and acute andchronic GVHD were estimated based on cumulative incidence curves [15].
Competing events were death without relapse for relapse, relapse for NRM,
death without engraftment for neutrophil and platelet engraftment, and
death or relapse without GVHD for acute and chronic GVHD. The groups
were compared using Gray’s test [16]. The Cox proportional hazards model
was used to evaluate the effect of confounding variables on OS, and the Fine
and Gray proportional hazards model was used for the other endpoints [17].
Based on the report by the Center for International Blood and Marrow
Transplant Research, we classiﬁed the conditioning regimens as myeloa-
blative if total body irradiation >8 Gy, oral busulfan 9 mg/kg, i.v. busulfan
7.2 mg/kg, or melphalan >140 mg/m2 was used in the conditioning
regimen; otherwise, the conditioning regimen was classiﬁed as reduced
intensity [18]. For patients with insufﬁcient data regarding dosages of the
agents used in the conditioning regimen, we used the information on
conditioning intensity (myeloablative or reduced intensity) reported by the
treating clinicians. We deﬁned AML and ALL in ﬁrst or second remission,
CML in ﬁrst or second chronic phase or accelerated phase, and MDS with
refractory anemia or refractory anemia with ringed sideroblasts as standard
risk, and all other conditions as high risk.
The following possible confounding variables were considered: recip-
ient age group (0-5 years, 6-15 years, 16-49 years, or 50 years at trans-
plantation), matching of ABO blood type between the recipient and UCB
(match or major, minor, or bidirectional MM), recipient sex, sex MM
between recipient and UCB (match, male donorefemale recipient, or female
donoremale recipient), disease (AML, ALL, CML, or MDS), disease status
before transplantation (standard or high risk), type of conditioning regimen
(myeloablative or reduced intensity), type of GVHD prophylaxis (calcineurin
inhibitor plus methotrexate, calcineurin inhibitor only, others), and year of
transplantation (1998-2004 or 2005-2009). Factors other than HLA MM and
total nucleated cell (TNC) dose category were selected in a stepwise manner
from the model with a variable retention criterion of P < .05. HLA MM and
TNC dose category (10.0, 5.0-9.9, 2.5-4.9, 2.0-2.4, and <2.0  107/kg) were
then added to the ﬁnal model. All tests were 2-sided, and a P value<.05 was
considered statistically signiﬁcant. All statistical analyses were performed
with Stata version 12 (StataCorp, College Station, TX) and EZR (Saitama
Medical Center, Jichi Medical University, Saitama, Japan), a graphical user
interface for R 2.13.0 (R Foundation for Statistical Computing, Vienna,
Austria) [19]. More precisely, EZR is a modiﬁed version of R commander
(version 1.6-3) designed to add statistical functions used frequently used in
biostatistics.
RESULTS
Patient Characteristics
Table 1 summarizes patient and transplant characteris-
tics. The median age of the recipients at transplantation was
41 years (range, 0-82 years), and 2300 patients (77%) were
age 16 years. Diagnoses for transplantation were AML in
1606 patients, ALL in 893, CML in 135, and MDS in 343. Half
of the patients had standard-risk disease. UCBT was per-
formed between 1998 and 2004 in 1153 patients (39%) and
between 2005 and 2009 in 1824 patients (61%). The combi-
nation of a calcineurin inhibitor (tacrolimus or cyclosporine)
and methotrexate was used in 62% of patients, whereas
a calcineurin inhibitor alone was used in 22% of patients.
Some 40% of patients received a UCB unit containing
<2.5  107/kg TNCs, and 45% received a UCB unit containing
2.5-4.9  107/kg TNCs. Roughly 12% of patients received
5.0  107/kg TNCs, but 93% of these patients were age <16
years. Median body weight was 17 kg (range, 4-68 kg) for the
children and 55 kg (range, 24-165 kg) for the adults. HLAMM
was categorized as follows: HLA match in both the GVH and
HVG directions (GVH 0/HVG 0 MM group; n ¼ 273 [9%]), 1-2
antigen MMs in the GVH direction but 0 MMs in the HVG
direction (GVH 1-2/HVG 0 MM group; n ¼ 150 [5%]), 1-2
antigen MMs in the HVG direction but 0 MM in the GVH
direction (GVH 0/HVG 1-2 MM group; n ¼ 136 [5%]), 1
antigen MM in both the GVH and HVG directions at the same
locus (GVH 1/HVG 1 MM group; n ¼ 716 [24%]), 2 antigen
MMs in both the GVH and HVG directions (GVH 2/HVG 2MM
group; n ¼ 1170 [39%]), 2 antigen MMs in the GVH direction
and 1 antigen MM in the HVG direction (GVH 2/HVG 1 MM
group; n ¼ 231 [8%]), 1 antigen MM in the GVH direction and
Table 1
Patient Characteristics
Characteristic Total Children (0-15 Years) Adults (16þ Years)
Recipient age at UCBT, years, median (range) 41 (0-82) 5 (0-15) 49 (16-82)
Recipient age at UCBT, years, n (%)
0-9 511 (17) 511 (75) 0 (0)
10-19 272 (9) 166 (25) 106 (5)
20-29 287 (10) 0 (0) 287 (12)
30-39 371 (12) 0 (0) 371 (16)
40-49 422 (14) 0 (0) 422 (18)
50-59 625 (21) 0 (0) 625 (27)
60 489 (16) 0 (0) 489 (21)
ABO matching, n (%)
Match 994 (33) 248 (37) 746 (32)
Minor 815 (27) 174 (26) 641 (28)
Major 704 (24) 149 (22) 555 (24)
Bidirectional 458 (15) 104 (15) 354 (15)
Missing 6 (0) 2 (0) 4 (0)
Recipient sex, n (%)
Female 1316 (44) 305 (45) 1011 (44)
Male 1661 (56) 372 (55) 1289 (56)
Donorerecipient sex match, n (%)
Match 1157 (39) 290 (43) 867 (38)
Male donor and female recipient 635 (21) 153 (23) 482 (21)
Female donor and male recipient 768 (26) 172 (25) 596 (26)
Missing 417 (14) 62 (9) 355 (15)
Diagnosis, n (%)
AML 1606 (54) 234 (35) 1372 (60)
ALL 893 (30) 391 (58) 502 (22)
CML 135 (5) 11 (2) 124 (5)
MDS 343 (12) 41 (6) 302 (13)
Disease risk at UCBT, n (%)
Standard risk 1385 (47) 423 (62) 962 (42)
High risk 1450 (49) 226 (33) 1224 (53)
Missing 142 (5) 28 (4) 114 (5)
Conditioning regimen, n (%)
Myeloablative 1980 (67) 585 (86) 1395 (61)
Reduced intensity 986 (33) 86 (13) 900 (39)
Missing 11 (0) 6 (1) 5 (0)
In vivo T cell depletion (ATG or alemtuzumab), n (%)
No 2935 (99) 665 (98) 2270 (99)
Yes 42 (1) 12 (2) 30 (1)
GVHD prophylaxis, n (%)
CSA only 250 (8) 59 (9) 191 (8)
TAC only 407 (14) 27 (4) 380 (17)
CSA þ MTX 1105 (37) 209 (31) 896 (39)
TAC þ MTX 755 (25) 241 (36) 514 (22)
CSA þ MMF 104 (3) 0 (0) 104 (5)
TAC þ MMF 148 (5) 6 (1) 142 (6)
CSA þ corticosteroid 87 (3) 67 (10) 20 (1)
TAC þ corticosteroid 34 (1) 26 (4) 8 (0)
Other 66 (2) 33 (5) 33 (1)
Missing 21 (1) 9 (1) 12 (1)
Year of UCBT, n (%)
1998-2004 1153 (39) 389 (57) 764 (33)
2005-2009 1824 (61) 288 (43) 1536 (67)
TNC dose when frozen, n (%)
10.0  107/kg 99 (3) 99 (15) 0 (0)
5.0-9.9  107/kg 259 (9) 234 (35) 25 (1)
2.5-4.9  107/kg 1344 (45) 268 (40) 1076 (47)
2.0-2.4  107/kg 924 (31) 44 (6) 880 (38)
<2.0  107/kg 275 (9) 21 (3) 254 (11)
Missing 76 (3) 11 (2) 65 (3)
Weight, kg, median (range) 52 (4-165) 17 (4-68) 55 (24-165)
HLA MM
0 MM 273 (9) 144 (21) 129 (6)
1-2 MM/GVH only 150 (5) 45 (7) 105 (5)
1-2 MM/rejection only 136 (5) 39 (6) 97 (4)
1 bidirectional MM 716 (24) 314 (46) 402 (17)
2 bidirectional MM 1170 (39) 98 (14) 1072 (47)
2 MM: bidirectional þ GVHD 231 (8) 16 (2) 215 (9)
2 MM: bidirectional þ rejection 264 (9) 19 (3) 245 (11)
2 MM: GVHD þ rejection 37 (1) 2 (0) 35 (2)
ATG indicates antithymocyte globulin; CSA, cyclosporine; MMF, mycophenolate mofetil; MTX, methotrexate; TAC, tacrolimus; 0 MM, HLA match in both the
GVH and HVG directions; 1-2 MM/GVH only, antigen MMs in the GVH direction and 0 MMs in the HVG direction; 1-2 MM/rejection only, 1 or 2 antigen MMs in
the HVG direction and no MMs in the GVH direction; 1 bidirectional MM, 1 antigen MM in both the GVH and HVG directions at the same locus; 2 bidirectional
MM, 2 antigen MMs in both the GVH and HVG directions; 2 MM: bidirectional þ GVHD, 2 antigen MMs in the GVH direction and 1 antigen MM in the HVG
direction; 2 MM: bidirectionalþ rejection, 1 antigen MM in the GVH direction and 2 antigen MMs in the HVG direction; 2 MM: GVHDþ rejection, 1 antigen MM
in the GVH direction at one locus and 1 antigen MM in the HVG direction at another locus.
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group; n¼ 264 [9%]), and 1 antigen MM in the GVH direction
at 1 locus and 1 antigen MM in the HVG direction at another
locus (GVH 1/HVG 1 2-antigen MM group; n ¼ 37 [1%]).A
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3OS, Relapse, and NRM
The median follow-up period in survivors was 2.2 years
(range, 0.0-11.1 years). The 2-year OS rate was 0.46 (95%
conﬁdence interval [CI], 0.44-0.48) (Figure 1). To clarify the
impact of HLA MM in each vector, the GVH 1/HVG 1 MM
group was considered the reference group in the multivar-
iate analyses, in accordance with the approach of Stevens
et al. [9], and the following hazard ratios (HRs) were adjusted
for the other signiﬁcant variables, including TNC dose cate-
gory. The GVH 1-2/HVG 0 MM (HR, 0.88; 95% CI, 0.69-1.13;
P ¼ .317), the GVH 0/HVG 1-2 MM (HR, 0.95; 95% CI, 0.74-
1.22; P ¼ .670), and other groups were not associated with
overall mortality compared with the GVH 1/HVG 1 MM
group (Table 2 and Figure 1). The GVH 0/HVG 0 MM group0 1 2 3 4 5
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Figure 1. OS of total patients (A) and patients grouped according to HLA MM
category (B). GVH0 HVG0, HLA match in both the GVH and HVG directions;
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the GVH 1/HVG 1 MM group (HR, 0.79; 95% CI, 0.64-0.97;
P ¼ .025); however, in both the child and adult cohorts, the
association was not signiﬁcant, owing in part to a lack of
statistical power. The GVH 1/HVG 1 2-antigen MM group,
which was represented mostly in the adult cohort, was
associated with lower overall mortality compared with the
GVH 1/HVG 1 MM group (HR, 0.55; 95% CI, 0.35-0.87;
P ¼ .012).
We performed an additional analysis according to the
HLA matching criteria used in the United States and Europe
(HLA-A and -B for antigen level and -DRB1 for allele level)
(Supplemental Table 1). Consistent with the result obtained
using our criteria (HLA-A, -B, and -DR for antigen level), there
were no differences in the impact of the MM direction (GVH
or HVG) on OS. The difference in OS between the GVH 0/HVG
0 MM and GVH 1/HVG 1 MM groups was not signiﬁcant in
this analysis.
The cumulative incidence rates of relapse and NRM at 2
years were 0.34 (95% CI, 0.32-0.36) and 0.26 (95% CI, 0.24-
0.27), respectively. There was no difference in the incidence
of relapse between the GVH 1/HVG 1 MM and any other MM
group (Table 3 and Figure 2). The GVH 1-2/HVG 0 MM group
was signiﬁcantly associated with lower NRM compared with
the GVH 1/HVG 1 MM group (HR, 0.65; 95% CI, 0.44-0.98;
P ¼ .040) (Table 3 and Figure 2), but only in the child cohort
(child, P ¼ .048; adult, P ¼ .215).
Because our cohorts were mainly adults, and most adults
received a TNC dose of 2.0-4.9  107/kg, we performed an
additional analysis in the subset of adults who received a TNC
dose of 2.0-2.4  107/kg or 2.5-4.9  107/kg (Supplemental
Table 2). In the subset of adults who received a TNC dose of
2.0-2.4  107/kg, compared with the GVH 1/HVG 1 MM
group, the GVH 0/HVG 0 MM group was associated with
lower overall mortality (P ¼ .027) and NRM (P ¼ .007) and a
higher incidence of relapse (P ¼ .028), and the GVH 2/HVG 2
MM group was associated with lower overall mortality
(P ¼ .001) and NRM (P ¼ .008). The GVH 1-2/HVG 0 MM
group was signiﬁcantly associated with lower NRM
compared with the GVH 1/HVG 1 MM group (P ¼ .033). In
the subset of adults who received a TNC dose of 2.5-
4.9  107/kg, no HLA MM group was associated with overall
mortality, relapse, or NRM, except for lower overall mortality
in the GVH 1/HVG 1 2-antigen MM group compared with the
GVH 1/HVG 1 MM group (P ¼ .046).Table 3
Relapse and NRM
HLA MM category Relapse*
Number HR 95% CI
0 MM 258 1.07 (0.84-1.37)
1-2 MM/GVH only 147 1.20 (0.90-1.59)
1-2 MM/rejection only 131 1.18 (0.84-1.64)
1 bidirectional MM 667 1.00
2 bidirectional MM 1106 0.99 (0.83-1.19)
2 MM: bidirectional þ GVHD 217 1.00 (0.76-1.33)
2 MM: bidirectional þ rejection 243 1.27 (0.99-1.63)
2 MM: GVHD þ rejection 36 0.64 (0.32-1.24)
* Other signiﬁcant variables were recipient age group, 0-5 years (reference, 1.00),
CI, 0.52-0.97; P ¼ .030), 50 years (HR, 0.72; 95% CI, 0.52-0.98; P ¼ .040); diagnosis
1.33, 95% CI, 0.99-1.79, P ¼ .059), MDS (HR, 0.67, 95% CI, 0.51-0.87, P ¼ .003); disea
P < .001); GVHD prophylaxis, CSA/TAC þ MTX (reference, 1.00), CSA/TAC only (H
P ¼ .145).
y Other signiﬁcant variables were recipient age group, 0-5 years (reference, 1.00),
CI, 1.29-3.22; P ¼ .002), 50 years (HR, 3.52; 95% CI, 2.24-5.52; P < .001); GVHD pr
1.60-2.26; P< .001), others (HR, 1.42; 95% CI, 1.14-1.75; P¼ .001), year of transplan
P < .001).Neutrophil and Platelet Engraftment
The cumulative incidence rates of neutrophil and platelet
engraftment in our study cohort were 0.76 (95% CI, 0.74-0.77)
and 0.57 (95% CI, 0.55-0.59), respectively. The GVH 1-2/HVG
0 MM group was marginally associated with better neutro-
phil and platelet engraftment kinetics compared with the
GVH 1/HVG 1 MM group (neutrophil engraftment: HR, 1.18;
95% CI, 0.98-1.42; P ¼ .081; platelet engraftment: HR, 1.23;
95% CI, 1.00-1.51; P ¼ .053) (Table 4 and Figure 3). The im-
pact on neutrophil engraftment was signiﬁcant only in the
adult cohort (child, P ¼ .496; adult, P ¼ .045).Acute and Chronic GVHD
In all engrafted patients, the cumulative incidence rates of
grade II-IV and III-IV acute GVHD were 0.45 (95% CI, 0.43-
0.47) and 0.15 (95% CI, 0.14-0.17), respectively. The GVH 0/
HVG 0 MM group was signiﬁcantly associated with a lower
incidence of grade II-IV acute GVHD compared with the GVH
1/HVG 1 MM group (HR, 0.70; 95% CI, 0.54-0.90; P ¼ .006)
(Supplemental Table 3 and Figure 4), but only in the child
cohort (child, P ¼ .002; adult, P ¼ .506). The GVH 0/HVG
0 MM group was marginally associated with a lower inci-
dence of chronic GVHD comparedwith the GVH 1/HVG 1MM
group (HR, 0.72; 95% CI, 0.51-1.00; P ¼ .050).DISCUSSION
This nationwide retrospective study that included a large
number of both pediatric and adult patients allowed us to
consider an adequate number of patients who underwent
UCBT with an HLA MM only in the GVH direction or only in
the HVG direction, and to analyze the impact of anMM in the
GVH or HVG direction on clinical outcomes after a single
UCBT. Neither the GVH 1-2/HVG 0 MM group nor the GVH 0/
HVG 1-2 MM group was associated with overall mortality
compared with the GVH 1/HVG 1 MM group. The point
estimates of HRs of the GVH 1-2/HVG 0 MM and GVH 0/HVG
1-2 MM groups compared with the GVH 1/HVG 1 MM group
were similar and both <1 (HR, 0.88 and 0.95, respectively),
suggesting that HLA MMs in the GVH and HVG directions
post-UCBT do not have different effects on OS. This ﬁnding
does not support the conclusion of Stevens et al. [9], who
recommended using UCB units with an HLA MM only in the
GVH direction and avoiding units with an HLA MM only in
the HVG direction.NRMy
P Value Number HR 95% CI P Value
.560 258 0.74 (0.53-1.02) .063
.215 147 0.65 (0.44-0.98) .040
.338 131 0.81 (0.55-1.19) .292
Reference 667 1.00 Reference
.930 1106 0.88 (0.72-1.07) .191
.979 217 0.81 (0.60-1.10) .184
.060 243 0.66 (0.49-0.91) .010
.184 36 0.61 (0.32-1.16) .131
6-15 years (HR, 0.61; 95% CI, 0.44-0.84; P¼ .002), 16-49 years (HR, 0.71; 95%
, AML (reference, 1.00), ALL (HR, 1.11, 95% CI, 0.94-1.30, P ¼ .210), CML (HR,
se risk, standard risk (reference, 1.00), high risk (HR, 2.93; 95% CI, 2.54-3.39;
R, 0.72; 95% CI, 0.61-0.86; P < .001), others (HR, 0.87; 95% CI, 0.71-1.05;
6-15 years (HR, 1.44; 95% CI, 0.90-2.30; P¼ .128), 16-49 years (HR, 2.04; 95%
ophylaxis, CSA/TAC þMTX (reference, 1.00), CSA/TAC only (HR, 1.90; 95% CI,
tation, 1998e2004 (reference, 1.00), 2005-2009 (HR, 0.71; 95% CI, 0.61-0.83;
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Figure 2. Relapse and NRM.
J. Kanda et al. / Biol Blood Marrow Transplant 19 (2013) 247e254252Several differences in patient background between the
study of Stevens et al. [9] and the present study warrant
clariﬁcation. The ﬁrst difference is in the age distribution ofTable 4
Neutrophil and Platelet Engraftment
HLA MM Category Neutrophil Engraftment*
Number HR 95% CI
0 MM 272 1.03 (0.88-1.20)
1-2 MM/GVH only 149 1.18 (0.98-1.42)
1-2 MM/rejection only 136 1.01 (0.82-1.26)
1 bidirectional MM 716 1.00
2 bidirectional MM 1167 0.98 (0.87-1.09)
2 MM: bidirectional þ GVHD 231 0.91 (0.76-1.08)
2 MM: bidirectional þ rejection 264 0.86 (0.72-1.02)
2 MM: GVHD þ rejection 37 1.40 (1.03-1.89)
* Other signiﬁcant variables were TNC category, 2.5-4.9 107/kg (reference, 1.00)
1.26; 95% CI, 1.05-1.52; P ¼ .015), 2.0-2.4  107/kg (HR, 0.87; 95% CI, 0.79-0.95; P ¼
(reference, 1.00), ALL (HR, 1.11, 95% CI, 1.00-1.22, P ¼ .040), CML (HR, 0.87, 95% CI,
standard risk (reference, 1.00), high risk (HR, 0.74; 95% CI, 0.67-0.80; P < .001); GV
95% CI, 1.04-1.30; P¼ .010), others (HR, 1.09; 95% CI, 0.96-1.23; P¼ .169), year of tra
1.33; P < .001).
y Other signiﬁcant variables were TNC category, 2.5-4.9 107/kg (reference, 1.00)
1.26; 95% CI, 1.01-1.57; P ¼ .040), 2.0-2.4  107/kg (HR, 0.95; 95% CI, 0.84-1.06; P
group, 0-5 years (reference, 1.00), 6-15 years (HR, 1.00; 95% CI, 0.79-1.25; P¼ .971)
CI, 0.55-0.90; P ¼ .006); recipient sex, female (reference, 1.00), male (HR, 0.90; 95%
(HR, 0.58; 95% CI, 0.53-0.64; P < .001); GVHD prophylaxis, CSA/TAC þ MTX (refere
0.88; 95% CI, 0.76-1.01; P ¼ .074), and year of transplantation, 1998-2004 (referenpatients. Stevens et al.’s series included 907 pediatric
patients age <16 years and 295 adult patients; in contrast,
our series included 677 pediatric patients and 2300 adult
patients, which can provide useful information for both
pediatric and adult transplant physicians. Since the cell doses
of UCB units in child and adult cohorts are signiﬁcantly
different, which may affect the impact of HLA MM, we per-
formed stratiﬁed analyses in the child and adult cohorts. Our
results consistently showed that the direction of MM had no
apparent impact on overall mortality in either cohort.
Consistent with the results of Stevens et al. [9], the GVH 1-2/
HVG 0 MM group was associated with lower NRM in the
child cohort, but this advantage was offset by a higher inci-
dence of relapse in this cohort. A second difference between
the 2 studies is in conditioning regimens. A myeloablative
regimen was used in 92% of the patients in the Stevens et al.
study, compared with 67% in our study. Consequently, we
performed a separate analysis in the patients who received
a myeloablative regimen and conﬁrmed that the direction of
MM had no apparent impact on overall mortality (data not
shown).
The thirddifference between the 2 studies relates toGVHD
prophylaxis. Cyclosporine and steroids were used as GVHD
prophylaxis in 62% of the patients in the Stevens et al. study,
but in only 3% of the patients (10% of the child cohort) in our
study, which might have affected outcomes. The fourth
difference is in the number of patients with an HLA MM only
in theGVHdirection or only in theHVGdirection. The Stevens
et al. study included 35 patients with a GVH 1-2/HVG 0 MM
and 22 patients with a GVH 0/HVG 1-2 MM in the overall
mortality analysis, compared with 150 and 136 patients,
respectively, in our study. Finally, the level of HLA typing used
to determine the number of HLAMMs differed between the 2
studies. In the present study, MMs in HLA-DR loci were
counted at the antigen level in accordance with current
practice in Japan, whereas Stevens et al. counted HLA-DRB1
MMs at the allele level. Consequently, we performed an
additional analysis using the sameHLAmatching criteria as in
previous studies from the United States and Europe (HLA-A
and -B for antigen level and -DRB1 for allele level), and
reached a similar conclusion that an MM only in the GVH or
only in the HVG direction had no impact on overall mortality.Platelet Engraftmenty
P Value Number HR 95% CI P Value
.718 272 1.06 (0.88-1.27) .559
.081 149 1.23 (1.00-1.51) .053
.899 136 0.84 (0.66-1.07) .164
Reference 714 1.00 Reference
.672 1166 0.96 (0.85-1.10) .590
.278 230 0.91 (0.74-1.13) .406
.089 264 0.98 (0.80-1.19) .816
.030 37 2.21 (1.46-3.33) <.001
,10.0 107/kg (HR, 1.76; 95% CI, 1.33-2.33; P< .001), 5.0-9.9 107/kg (HR,
.003), <2.0  107/kg (HR, 0.82; 95% CI, 0.71-0.95; P ¼ .007); diagnosis, AML
0.73-1.04, P ¼ .124), MDS (HR, 0.88, 95% CI, 0.75-1.04, P ¼ .129); disease risk,
HD prophylaxis, CSA/TAC þ MTX (reference, 1.00), CSA/TAC only (HR, 1.16;
nsplantation, 1998-2004 (reference, 1.00), 2005-2009 (HR, 1.21; 95% CI, 1.11-
,10.0 107/kg (HR, 1.49; 95% CI, 1.09-2.03; P¼ .013), 5.0-9.9 107/kg (HR,
¼ .365), <2.0  107/kg (HR, 0.81; 95% CI, 0.67-0.97; P ¼ .022); recipient age
, 16-49 years (HR, 0.99; 95% CI, 0.77-1.26; P¼ .909), 50 years (HR, 0.70; 95%
CI, 0.82-0.99; P¼ .034); disease risk, standard risk (reference, 1.00), high risk
nce, 1.00), CSA/TAC only (HR, 0.81; 95% CI, 0.71-0.91; P ¼ .001), others (HR,
ce, 1.00), 2005-2009 (HR, 1.26; 95% CI, 1.14-1.40; P < .001).
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Figure 3. Neutrophil and platelet engraftment.
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Figure 4. Acute and chronic GVHD.
J. Kanda et al. / Biol Blood Marrow Transplant 19 (2013) 247e254 253Similar to Stevens et al. [9], we found a tendency for
better neutrophil and platelet engraftment kinetics in the
GVH 1-2/HVG 0MM group. This ﬁnding suggests that an HLA
MM in the GVH direction enhances engraftment by eradi-
cating or suppressing the host residual immune cells
responsible for the rejection or inhibition of donor cell
engraftment. In contrast to our ﬁndings, Matsuno et al. [8]
analyzed the impact of GVH/HVG MM on 152 patients who
underwent a single UCBT in a single center, and found that
the presence of a 2-antigen MM in the GVH direction was
associated with slower and lower neutrophil engraftment
compared with a 0- or 1-antigen MM in the GVH direction.
Because Matsuno et al. used only a calcineurin inhibitor for
GVHD prophylaxis in all of the patients in their cohort, we
recategorized the HLA MM group according to HLA category
(GVH 0-1/HVG 0-1 MM, GVH 0e1/HVG 2 MM, GVH 2/HVG 0-
1 MM, and GVH 2/HVG 2 MM) and performed additional
analyses inwhich patients were stratiﬁed according to GVHD
prophylaxis (calcineurin inhibitor plus methotrexate, calci-
neurin inhibitor only, or other). Similar to the ﬁndings of
Matsuno et al., an MM in the GVH direction was signiﬁcantly
associated with a lower incidence of engraftment in patients
who received only a calcineurin inhibitor (data not shown).
In contrast, an MM in the GVH direction was associated witha higher incidence of engraftment in patients who received
a calcineurin inhibitor plus methotrexate. These ﬁndings
suggest that the impact of HLA MM differs according to
GVHD prophylaxis. A possible explanation for the different
J. Kanda et al. / Biol Blood Marrow Transplant 19 (2013) 247e254254effects of GVHD prophylaxis on engraftment is the high
incidence of hemophagocytic syndrome (HPS) and pre-
engraftment immune reaction in patients who received
only a calcineurin inhibitor as GVHD prophylaxis [20,21].
Takagi et al. [20] reported HPS in 20 of 119 patients who
underwent UCBT with mostly tacrolimus alone as GVHD
prophylaxis, resulting in a high incidence of graft failure.
Less-intensive GVHD prophylaxis may enhance the immune
reaction caused by donor T cells that recognize the HLA MM
antigen in the GVH direction in the early phase after trans-
plantation, which could lead to HPS or similar conditions and
decrease the rate of neutrophil engraftment. These ﬁndings
demonstrate the need for a prospective study using uniform
GVHD prophylaxis to further evaluate the impact of HLA MM
on neutrophil engraftment.
This study has several limitations. First, the patients’
heterogeneous backgrounds might have produced statistical
bias, although we attempted to reduce this bias by adjusting
the impact in the multivariate analyses. Second, the number
of subjects in each HLA MM group category was limited.
Nevertheless, the number of subjects in the GVH 1-2/HVG
0 and GVH 0/HVG 1-2 MM groups was much greater than
that in previous studies [8,9]. Third, we might have under-
estimated the degree of HLA MM, given our incomplete
allelic and HLA-C antigen information; for example, the
group that had only an HLA MM in the GVH direction might
have included an allelic MM in the HVG direction. A potential
HLA-C antigen MM or KIR ligand MM also might have
affected outcomes, but we did not evaluate HLA-C in the
present study. The foregoing issues might have weakened
the power of this study to detect differences.
In conclusion, our ﬁndings do not support a strategy for
selecting UCB donors based on the direction of the HLA MM,
although GVH 1-2/HVG 0MMsmay be associatedwith better
neutrophil engraftment, particularly when a calcineurin
inhibitor plus other immunosuppressive agents, such as
methotrexate, are used for GVHD prophylaxis. The impact of
HLA MMs in only the GVH direction remains to be clariﬁed
further under a uniform GVHD prophylaxis regimen.ACKNOWLEDGMENTS
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